Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000419913

Medchemexpress LLC Paris saponin VII | 68124-04-9 | 5 MG
SDP

Catalog No. 5000419913
Encompass_Preferred

Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin from *Trillium tschonoskii*. It induces apoptosis and robust autophagy in K562/ADR cells, demonstrating potential for leukemia treatment. Its action involves Akt/MAPK and P-gp inhibition, attenuating mitochondrial membrane potential, increasing pro-apoptotic proteins like Bax and cytochrome c, and decreasing anti-apoptotic proteins such as Bcl-2, caspases, PARP-1, and p-Akt.

  • Isolated from *Trillium tschonoskii*.
  • Induces apoptosis and autophagy in K562/ADR cells.
  • Inhibits Akt/MAPK and P-gp.
  • Attenuates mitochondrial membrane potential.
  • Modulates apoptosis-related proteins (e.g., Bax, Bcl-2, caspases).
  • Potential for leukemia treatment.
  • Inhibits adriamycin-resistant leukemia cell growth.
  • Suppresses cell proliferation via G0/G1 arrest.
  • Enhances adriamycin's anticancer efficacy in xenograft models.

Catalog No. 50-004-19913 Supplier Medchemexpress LLC Supplier No. HYN35845MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin from *Trillium tschonoskii*. It induces apoptosis and robust autophagy in K562/ADR cells, demonstrating potential for leukemia treatment. Its action involves Akt/MAPK and P-gp inhibition, attenuating mitochondrial membrane potential, increasing pro-apoptotic proteins like Bax and cytochrome c, and decreasing anti-apoptotic proteins such as Bcl-2, caspases, PARP-1, and p-Akt.

  • Isolated from *Trillium tschonoskii*.
  • Induces apoptosis and autophagy in K562/ADR cells.
  • Inhibits Akt/MAPK and P-gp.
  • Attenuates mitochondrial membrane potential.
  • Modulates apoptosis-related proteins (e.g., Bax, Bcl-2, caspases).
  • Potential for leukemia treatment.
  • Inhibits adriamycin-resistant leukemia cell growth.
  • Suppresses cell proliferation via G0/G1 arrest.
  • Enhances adriamycin's anticancer efficacy in xenograft models.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.